Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 252

1.

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.

Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D.

Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2569-74.

2.

Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography.

Ginovart N, Galineau L, Willeit M, Mizrahi R, Bloomfield PM, Seeman P, Houle S, Kapur S, Wilson AA.

J Neurochem. 2006 May;97(4):1089-103. Epub 2006 Apr 5.

3.

Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.

Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Långström B.

Neurology. 1996 May;46(5):1430-6.

PMID:
8628494
4.

Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects.

Dewey SL, Smith GS, Logan J, Brodie JD, Simkowitz P, MacGregor RR, Fowler JS, Volkow ND, Wolf AP.

Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11816-20.

5.

Effect of amphetamine-induced dopamine release on radiotracer binding to D1 and D2 receptors in rat brain striatal slices.

Gifford AN, Park MH, Kash TL, Herman LM, Park EH, Gatley SJ, Volkow ND.

Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):413-8.

PMID:
11111836
6.

Kinetic modeling of [11C]raclopride: combined PET-microdialysis studies.

Endres CJ, Kolachana BS, Saunders RC, Su T, Weinberger D, Breier A, Eckelman WC, Carson RE.

J Cereb Blood Flow Metab. 1997 Sep;17(9):932-42.

7.

Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat.

Egerton A, Ahmad R, Hirani E, Grasby PM.

Psychopharmacology (Berl). 2008 Nov;200(4):487-96. doi: 10.1007/s00213-008-1226-4. Epub 2008 Jul 3.

PMID:
18597077
8.

GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [(11)C]raclopride continuous infusion PET scans.

Villemagne VL, Wong DF, Yokoi F, Stephane M, Rice KC, Matecka D, Clough DJ, Dannals RF, Rothman RB.

Synapse. 1999 Sep 15;33(4):268-73.

PMID:
10421707
9.

Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels.

Dewey SL, Smith GS, Logan J, Brodie JD, Fowler JS, Wolf AP.

Synapse. 1993 Apr;13(4):350-6.

PMID:
8480281
10.

Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography.

Hietala J, Syvälahti E, Vuorio K, Någren K, Lehikoinen P, Ruotsalainen U, Räkköläinen V, Lehtinen V, Wegelius U.

Arch Gen Psychiatry. 1994 Feb;51(2):116-23.

PMID:
7905257
11.
12.

Temporal characterisation of amphetamine-induced dopamine release assessed with [11C]raclopride in anaesthetised rodents.

Houston GC, Hume SP, Hirani E, Goggi JL, Grasby PM.

Synapse. 2004 Mar 1;51(3):206-12.

PMID:
14666518
13.
14.

Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach.

Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L, Malhotra AK, Pickar D.

Synapse. 1998 Jun;29(2):142-7.

PMID:
9593104
15.

Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis.

Dewey SL, Smith GS, Logan J, Alexoff D, Ding YS, King P, Pappas N, Brodie JD, Ashby CR Jr.

J Neurosci. 1995 Jan;15(1 Pt 2):821-9.

17.
18.

Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion.

Carson RE, Breier A, de Bartolomeis A, Saunders RC, Su TP, Schmall B, Der MG, Pickar D, Eckelman WC.

J Cereb Blood Flow Metab. 1997 Apr;17(4):437-47.

20.
Items per page

Supplemental Content

Write to the Help Desk